Our Science • Dapirolizumab pegol

Clinical Study Information - Dapirolizumab pegol

Disease area studied	Abbreviated title	Phase	Study ID	Registry database	Study results	Lay summary	Publication (if available)
Systemic Lupus Erythematosus	A Phase 2b, randomized, double-blind, PBO-controlled, parallel-group, dose-ranging study followed by an observational period that will evaluate the efficacy of Dapirolizumab Pegol (DZP) in inducing disease control and the safety of DZP in subjects with moderately to severely active Systemic Lupus Erythematosus (SLE) who are receiving standard-of-care medications.	Phase 2	SL0023 Completed	NCT02804763 2015-004457-40	LINK		Furie, R. et al. Ann Rheum Dis 2019; 78 (Suppl. 2), p. 775
Systemic Lupus Erythematosus	The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.	Phase 3	SL0043 Ongoing	NCT04294667 2019-003406-27

Our Company